Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Targeting leukemic stem cells using humanized chimeric immunotoxin

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Madhumathi Jayaprakasam

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

M. Jayaprakasam1, S. Surapalli2, R.S. Verma2

Author affiliations

  • 1 Epidemiology And Communicable Diseases, Indian Council of Medical Research, 110029 - New Delhi/IN
  • 2 Indian Institute of Technology, 600025 - Chennai/IN
More

Resources

Cancer stem cells (CSC) are defined as cells with a tumor-initiating potential and are resistant to chemo-radiation therapy. Evasion of apoptosis is one of the hallmarks of human cancers attributed to CSCs. Human TRAIL/Apo-2L is a ligand of the TNF family that can trigger apoptotic cell death and has been demonstrated to induce apoptosis in a wide range of cancers. Interestingly, TRAIL receptor DR5 was found to be over-expressed in leukemic stem cells (LSCs). Inducing apoptosis in CSCs using TRAIL protein would be a novel and efficient strategy. We characterized and targeted the leukemic stem cells to induce self-death by TRAIL-based pathway. A fusion protein of IL2-TRAIL peptide was constructed to target leukemic cells over-expressing IL2 α receptor.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings